Accurate molecular analysis of tumors and their precursor lesions requires the extraction of specific subpopulations of cells (normal, preneoplastic and tumor) from a composite background of ...
Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback